General
Preferred name
MINOCYCLINE
Synonyms
MINOCYCLINE HYDROCHLORIDE ()
Minocycline HCl ()
Minocycline (hydrochloride) ()
Minocycline, Hydrochloride ()
Minocycline (CL 59806) HCl ()
Minocin ()
Dentomycin ()
Minocin 50 ()
Blemix 100 ()
Dynacin ()
Sebomin ()
Minocycline (as hydrochloride) ()
Minolira ()
Aknemin 50 ()
Acnamino ()
Sebren MR ()
Minogal ()
Amzeeq ()
NSC-141993 ()
Cyclomin ()
Minocin MR ()
Solodyn ()
Ximino ()
Arestin ()
Blemix 50 ()
Zilxi ()
Aknemin ()
Minocycline (hydrochloride hydrate) ()
P&D ID
PD009592
CAS
13614-98-7
10118-90-8
Tags
natural product
drug
available
Approved by
FDA
First approval
1971
Drug Status
investigational
approved
Max Phase
Phase 4
Drug indication
Antibacterial
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS Minocycline, the most lipid soluble and most active tetracycline antibiotic, is, like doxycycline, a long-acting tetracycline. Minocycline's effects are related to the inhibition of protein synthesis. In particular, the broad spectrum of activity that minocycline generally possesses means it also demonstrates activity against Neisseria meningitidis. However, the agent is no longer recommended to be employed as prophylaxis as it is capable of eliciting problematic adverse effects like dizziness and vertigo. Current research is examining the possible neuroprotective effects of minocycline against progression of Huntington's Disease, an inherited neurodegenerative disorder. The neuroprotective action of minocycline may include its inhibitory effect on 5-lipoxygenase, an inflammatory enzyme associated with brain aging.
DESCRIPTION 5-HT and NA reuptake inhibitor (SNRI) (Tocris Bioactive Compound Library)
Cell lines
3
Organisms
9
Compound Sets
19
AdooQ Bioactive Compound Library
A20954
Axon Medchem Screening Library
3381
Cayman Chemical Bioactives
14454
ChEMBL Approved Drugs
CHEMBL1200881
CHEMBL1434
ChEMBL Drugs
CHEMBL1200881
CHEMBL1434
DrugBank
DB01017
DrugBank Approved Drugs
DB01017
DrugCentral
1813
DrugCentral Approved Drugs
1813
MedChem Express Bioactive Compound Library
HY-17412
NCATS Inxight Approved Drugs
0020414E5U
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
minocycline-hcl
TargetMol Bioactive Compound Library
T1101
The Spectrum Collection
Tocris Bioactive Compound Library
3268
External IDs
68
Properties
(calculated by RDKit )
Molecular Weight
457.18
Hydrogen Bond Acceptors
9
Hydrogen Bond Donors
5
Rotatable Bonds
3
Ring Count
4
Aromatic Ring Count
1
cLogP
0.19
TPSA
164.63
Fraction CSP3
0.43
Chiral centers
4.0
Largest ring
6.0
QED
0.4
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Microbiology&virology
Anti-infection
Apoptosis
Membrane Transporter/Ion Channel
Metabolic Enzyme/Protease
Neuronal Signaling
Target
antibiotic
Bacterial
Calcium Channel
HIF/HIF Prolyl-Hydroxylase
MDM-2/p53
Potassium Channel
Primary Target
Antibiotics
MOA
Antibiotic
Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors
30S Ribosomal Protein Inhibitors
Protein Arginine Deiminase Inhibitors
Member status
member
Source data